Schering CEO Hassan Will Add Personal Touch To Allergy Business Turnaround
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough CEO Fred Hassan will be directly involved in reviving the firm's declining allergy business following the Rx-to-OTC switch of Claritin in December 2002
You may also be interested in...
Claritin Generic Competition Grows As Impax Version Granted FDA Approval
FDA approval of a generic version of Schering-Plough's OTC Claritin Reditabs (loratadine 10 mg) is expected to make further inroads into the $175 mil. product
Schering Turnaround Needs 5 Years, CEO Hassan Says; First Step: Buy Time
Schering-Plough CEO Fred Hassan's turnaround plan for the company relies on a careful balance of near-term markers coupled with a message of patience to buy time to execute a five- to seven-year plan
Schering GMP Criminal Investigation Continues After Consent Decree
Schering-Plough faces a potential criminal case regarding GMP violations after finalizing a consent agreement with FDA May 17